NCT03530696: T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

NCT03530696
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Therapeutic Antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, active, and unstable CNS metastases or carcinomatous meningitis that require treatment
https://ClinicalTrials.gov/show/NCT03530696

Comments are closed.

Up ↑